Business Wire

AXA Spain Chooses Akur8 to Transform Their Insurance Pricing Process

18.2.2021 16:00:00 EET | Business Wire | Press release

Share

Akur8, an Artificial Intelligence-based technological solution, and AXA Spain forge a partnership to contribute to the enhancement of AXA Spain’s pricing process. This deal marks the first partnership of Akur8 in Spain, one of Europe’s most competitive insurance markets, and the pursuit of Akur8’s expansion in Europe, with 6 countries of presence to date.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005004/en/

Specifically developed for insurers, Akur8’s solution enhances their pricing processes by automating risk and demand modeling, using transparent Artificial Intelligence proprietary technology. The core benefit for insurers is greater speed-to-accuracy, while maintaining full transparency and control on the models created.

AXA Spain is a leading insurer in Spain, with more than 3 million policyholders. With this partnership, AXA Spain will be able to significantly accelerate their time-to-market, offering more targeted prices with a higher degree of personalization to their customers, while fostering digital transformation in their space.

“Akur8 is thrilled to announce this partnership with AXA Spain, to provide them with a state-of-the-art solution to bring pricing sophistication to an entirely new level and bolster innovation in a process as strategic as pricing. AXA Spain is making a forerunner move in the Spanish market to bring more transparent and tailored prices to their customers,” says Samuel Falmagne, CEO at Akur8.

“Forging a partnership in Spain is a great milestone for Akur8’s expansion, reinforcing our footprint in Europe. AXA Spain will empower their team of 36 pricing actuaries to leverage Akur8 across all lines: personal, commercial and health, on both direct and intermediated business,” says Brune de Linares, Chief of Sales at Akur8.

“Our partnership with Akur8 reinforces our commitment towards customer-centricity, allowing us to bring as much personalization as possible to our policyholders, a founding pillar of our strategy in Spain. It also illustrates our push for differentiation through innovation and digital transformation, especially in complex times,” says Nuria Fernández, Retail Customer Offer Director and Actuarial Director at AXA Spain.

“Akur8 allows for a reduction in modeling time, enabling us to build new prices much faster and significantly decreasing our time-to-market, while increasing the productivity of our team,” says Enrique Rodríguez, Head of Personal Actuarial Department at AXA Spain.

About Akur8
Akur8 is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds - enabling customer lifetime value based price optimization.

About AXA Spain
AXA Spain, a member company of AXA, is a leading insurance player in Spain with a volume of €2.7Bn of premiums in 2019, especially in non-life, counting more than 3 million customers and 7,000 sales points. AXA Spain’s strategy is based on a multichannel approach, and relies on two main pillars, which are intermediaries and customers’ proximity as well as utmost personalization.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
For Akur8
Astrid Noël
+33 (0)7 68 24 93 27
astrid.noel@akur8-tech.com

For AXA Spain
Gema Rabaneda Martinez
+34 669 465 054
gema.rabaneda@axa.es

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 08:00:00 EET | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 27-31 in Denver, Colorado. Twenty-two abstracts will be presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare. “Galderma is on a path towards becoming the undisputed dermatology powerhouse and, as such, aims to set the bar for scientific excellence in the field. The range of data we are presenting at AAD shows the strength of our commitment to this across every part of our portfolio. Patients deserve sophisticated, effective solutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.” BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT GALDERMA Therapeutic Dermatology: Latest updat

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 08:00:00 EET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 05:36:00 EET | Press release

HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,

Access Advance Welcomes New VDP Pool Licensors and Releases Independent Economic Analysis Confirming FRAND Compliance24.3.2026 02:00:00 EET | Press release

Access Advance LLC today announced that Sharp Corporation, CB Cline, SK Planet, and Telechips, Inc have joined the Access Advance Video Distribution Patent Pool (VDP Pool) as Licensors, further expanding the pool's portfolio of patents for modern video codec technologies (HEVC, VVC, VP9, and AV1). The announcement coincides with the release of an independent economic analysis by Criterion Economics confirming that the VDP Pool's royalty structure is fair, reasonable, and nondiscriminatory (FRAND). Sharp, a global leader in consumer electronics and display technologies, brings decades of research and development in video processing and compression to the VDP Pool. The additions of CB Cline, SK Planet, and Telechips, Inc further expand the pool’s patent coverage. These additions reinforce the VDP Pool’s position as the leading licensing program for modern video codec technologies powering the streaming experiences of consumers worldwide. "Sharp, CB Cline, SK Planet, and Telechips each br

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye